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Abstract: During feeding, the gut microbiota contributes to the host energy acquisition and 
metabolic regulation thereby influencing the development of metabolic disorders such as 
obesity and diabetes. Short-chain fatty acids (SCFAs) such as acetate, butyrate, and 
propionate, which are produced by gut microbial fermentation of dietary fiber, are 
recognized as essential host energy sources and act as signal transduction molecules via  
G-protein coupled receptors (FFAR2, FFAR3, OLFR78, GPR109A) and as epigenetic 
regulators of gene expression by the inhibition of histone deacetylase (HDAC). Recent 
evidence suggests that dietary fiber and the gut microbial-derived SCFAs exert multiple 
beneficial effects on the host energy metabolism not only by improving the intestinal 
environment, but also by directly affecting various host peripheral tissues. In this review, we 
summarize the roles of gut microbial SCFAs in the host energy regulation and present an 
overview of the current understanding of its physiological functions.  
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1. Introduction 
Diet is a most important factor for daily nutrient acquisition. However, the dysregulation of energy 
homeostasis by excessive intake leads to obesity. Obesity is currently one of the most serious public 
health challenges worldwide, especially in the Western world, because of its increasing prevalence and 
its contribution to a complex of symptoms collectively called the “metabolic syndrome” [1,2].  
The progress of obesity is caused by a long-term imbalance between energy intake and expenditure, 
which in turn influences multiple effector pathways involving metabolites and hormones [3].  
Excessive food intake, especially of high-fat and sugar products, together with insufficient exercise and 
genetic susceptibility, are considered risk factors for developing obesity. Recent research has 
demonstrated that changes in the gut microbiota are closely linked with metabolic disorders such as 
obesity and type 2 diabetes [4–6]. One of the most important roles of the gut microbiota is to catabolize 
dietary fibers that are not completely hydrolyzed by the host enzymes during digestion [7]. The main 
products of intestinal bacterial fermentation of dietary fiber are short-chain fatty acids (SCFAs) such as 
acetate, propionate, and butyrate [8]. SCFAs can be used for de novo synthesis of lipids and glucose, 
which are the main energy sources for the host [9].  
2. Gut Microbial Composition and Metabolic Disease 
The gut microbiota is a complex of microorganisms including more than 100 trillion cells  
of 400 species, which is equivalent to ten times the total number of cells in the human body [10]. Because 
the majority of the gut microbes are strictly anaerobic their identification and functional analysis has 
been difficult. However, since the advent of metagenomics, it has been revealed that gut microbes play 
an important role in host metabolic and immune homeostasis. Recent studies indicate that the gut 
microbiota can be considered an environmental factor that affects host adiposity and can contribute to 
obesity [11,12]. The human microbiome contains 150 times more genes than the human genome [13]. 
Metagenomic analysis of the gut microbiome in obese mice and humans indicated that expression of 
genes involved in carbohydrate metabolism predominated. Transplantation of the microbiota from obese 
mice into the gut of germ-free mice significantly increased adiposity in the recipient mice in comparison 
with transplantation of a lean microbiota. Moreover, cohort studies in Europe and China revealed that, 
despite the ethnic and dietary differences patients with type 2 diabetes had a lower proportion of 
butyrate-producing and a larger proportion of non-butyrate-producing Clostridiales [14,15]. In addition, 
although the functions encoded by the metagenomes of butyrate-producing bacteria were comparable 
between European and Chinese, the prevalent bacterial taxa were markedly different in the two cohorts. 
This indicates that the gut microbiota is notably affected by diet and ethnicity. Roux-en-Y gastric bypass 
(RYGB) induces dramatic and sustained weight loss by restricting the amount of food that can be 
ingested, thereby improving insulin sensitivity and type 2 diabetes. RYGB is currently the most effective 
treatment for obesity. The resulting metabolic improvement cannot be explained by the reduced calorie 
intake alone; the altered gut physiology following RYGB contributes to an altered intestinal microbial 
ecology in mice, rats, and humans, which may contribute to the improved host metabolism. Liou et al. 
reported that the change in the gut microbiota upon transplantation of RYGB-related fecal microbiota 
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directly contributed to reduced weight and adiposity [16]. Therefore, the gut microbiota is considered an 
environmental factor that modulates the host metabolism and may contribute to metabolic disorder. 
3. Metabolic Beneficial Effects by SCFAs 
Recently, dietary fibers have gained increasing interest because they exert beneficial effects on 
metabolic functions such as body weight, food intake, glucose homeostasis, and insulin  
sensitivity [17,18]. Hence, dietary fiber intake reduces risk of inflammatory bowel disease, 
cardiovascular disease, colon cancer, obesity and diabetes [19,20]. In the last few decades, it has been 
hypothesized that SCFAs might play a key role in the prevention and treatment of metabolic syndrome, 
bowel disorders, and cancer [21–23]. With regard to the energy metabolism, butyrate improved insulin 
sensitivity and increased the energy expenditure in dietary-obese mice [24]. Butyrate and propionate 
were shown to protect against diet-induced obesity and regulated the gut hormones [25]. The oral 
administration of acetate improved glucose tolerance and suppresses obesity [26]. Clinical studies 
showed that the administration of SCFAs has a positive effect on the treatment of ulcerative colitis, 
Crohn's disease, and antibiotic-associated diarrhea and obesity [22,27–29]. In obese subjects, propionate 
significantly increased the release of postprandial plasma peptide YY (PYY) and glucagon-like peptide-1 
(GLP-1) from colonic cells, and reduced the energy intake. Inulin-propionate ester administrated at  
10 g per day over a period of 24 weeks significantly reduced weight gain, intra-abdominal adipose tissue 
distribution and intrahepatocellular lipid content, and improved insulin resistance in the inulin control 
group [29]. On the other hand, SCFAs also utilize as host energy source, therefore SCFAs are regarded 
as cause of increasing energy harvest from diet, linked to the obese phenotype by changes of gut 
microbiota composition. To clarify these controversial, the molecular mechanisms of SCFAs was  
next investigated. 
4. Molecular Mechanisms Involved in Host Metabolic Regulation by SCFAs 
As gut microbial SCFAs have been reported to exert beneficial effects on the host metabolism, in this 
paragraph we focus on the elucidation of the molecular mechanisms involved. Total SCFAs in gut lumen 
is ~100 mM, in blood is, portal ~400 μM and peripheral ~100 μM [30]. Hence, SCFAs exhibit the tissue 
specific physiological function by this concentration gradient. Butyrate enhances fatty acid oxidation and 
thermogenesis by increasing the expression of peroxisome proliferator-activated receptor-gamma 
coactivator-1α (PGC-1α) and the phosphorylation of adenosine-monophosphate-activated kinase (AMPK) 
in muscle and liver tissues, and the expression of PGC-1α and mitochondrial uncoupling protein-1  
(UCP-1) in brown adipose tissues [21]. Propionate and butyrate activate intestinal gluconeogenesis via 
a gut-brain neural circuit, thereby promoting metabolic benefits on body weight and glucose control [31]. 
Acetate reduces the appetite by changing the expression profiles of appetite regulatory neuropeptides in 
the hypothalamus through activation of TCA cycle [32]. Various studies that had been focused on the 
elucidation of the SCFA target molecules in the host demonstrated that G-protein-coupled receptors 
(GPCR) act as SCFA receptors [33,34]. 
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5. SCFA Receptors 
5.1. FFAR2/GPR43 
GPR43, also known as FFAR2 has been identified as an SCFA receptor and is mainly activated by 
acetate and propionate followed by butyrate [35,36]. FFAR2 is expressed in intestinal endocrine  
L-cells, where it stimulates the release of PYY and GLP-1. SCFA-induced FFAR2 activation was shown 
to promote the secretion of GLP-1 in mouse colonic primary cultures and in enteroendocrine STC-1  
cells [37]. Ffar2-deficient mice exhibited decreased SCFA-induced secretion of GLP-1 both in vitro and 
in vivo and improved insulin resistance. FFAR2 is abundantly expressed in adipose tissues as well. 
FFAR2 expression was significantly increased in white adipose tissues of high-fat-diet-induced obese 
mice in comparison with normal chow-fed mice [38]. In addition, SCFAs inhibited isoproterenol-induced 
lipolysis in a concentration-dependent manner in mouse 3T3-L1-derived adipocytes [38]. Ge et al. later 
demonstrated that this effect was dependent on FFAR2 using Ffar2-deficient mice [39]. Moreover, in 
white adipose tissues, FFAR2 activation by SCFAs suppressed adipose-specific insulin signaling, 
leading to the inhibition of fat accumulation [40]. Ffar2-deficient mice were shown to exhibit obesity, 
whereas mice overexpressing adipose-specific Ffar2 overexpressed mice exhibited leanness under 
normal conditions. However, these mouse strains did not exhibit theses respective phenotypes when 
grown under germ-free conditions or when treated with antibiotics. This indicated that the source of 
FFAR2 ligands was dependent on gut microbes and that FFAR2 regulates adipose-insulin signaling by 
sensing microbial SCFAs, thereby regulating fat accumulation and maintaining body energy homeostasis. 
Hence, FFAR2 activation by SCFAs promotes GLP-1 secretion in the gut and suppression of fat 
accumulation in adipose tissue, leading to increased insulin sensitivity. FFAR2 is also expressed in 
immune tissues. Gut microbiota and FFAR2 regulate inflammatory responses in colitis [41]. In addition, 
SCFAs regulate the size and function of the colonic pool of regulatory T cells and protect against colitis 
in a FFAR2-dependent manner in mice [42]. Since the inflammatory response is also related to the 
development of obesity and type 2 diabetes, the regulation of immune function via FFAR2 may be also 
related to the metabolic beneficial effects by SCFAs. 
5.2. FFAR3/GPR41 
FFAR3 has also been identified as an SCFA receptor. However, the ligand affinity to SCFAs differs 
between FFAR2 and FFAR3; FFAR3 is activated mainly by propionate and butyrate [35,36].  
Like FFAR2, FFAR3 is also expressed in PYY- and GLP-1-secreting endocrine L-cells, indicating its 
involvement in energy homeostasis [43]. The secretion of PYY and GLP-1 was shown to be reduced in 
primary cultured endocrine cells derived from Ffar3-deficient mice [37,44]. After transplantation of 
specific microbes to gnotobiotic mice, wild-type but not Ffar3-deficient mice showed an increase in PYY 
levels. Therefore, the secretion of PYY from intestinal L-cells is due to activation of FFAR3 by SCFAs 
produced by the gut microbes. FFAR3 is abundantly expressed in sympathetic ganglia as well [45]. 
FFAR3 activation by propionate increases the heart rate and energy expenditure through sympathetic 
activation. In addition, sympathetic activation by FFAR3 directly leads to noradrenalin release from the 
sympathetic neurons [46]. This indicates that FFAR3 regulates sympathetic activity by sensing the 
nutritional state, thereby maintaining body energy homeostasis. It has been reported that FFAR3 
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contributes to the improvement of insulin resistance by dietary fibers through activation of FFAR3 
expressed in the peripheral nerves by SCFAs produced by gut microbes [30]. This implies that FFAR3 
stimulation by SCFAs exhibits beneficial effects on the host metabolism via the peripheral nervous 
system and hormone secretion in the gut. Similar to FFAR2, FFAR3 affects the inflammatory response. 
Propionate was shown to affect bone marrow hematopoiesis in an FFAR3-dependent manner in mice, 
by inducing an enhanced generation of macrophage and dendritic cell precursors thereby influencing the 
allergic inflammatory response in airway disease via FFAR3 [47]. Therefore, FFAR3 may be involved 
in the beneficial effects of SCFAs on host metabolism through the regulation of immune responses. 
5.3. Other SCFA Receptors (GPR109A and OLFR78) 
GPR109A was first identified as a receptor for niacin and is also activated by β-hydroxybutryate and 
butyrate, but not by acetate and propionate [47]. The EC50 value for GPR109A activation by butyrate is 
approximately 1mM [47]. GPR109A is expressed in the epithelial cells of the colon and expression 
decreases in the absence of the gut microbiota in germ-free mice [48]. GPR109A activation by butyrate 
suppresses colonic inflammation and carcinogenesis by promoting anti-inflammatory properties in 
colonic macrophages and dendritic cells, which induce the differentiation of regulatory and  
IL10-producing T cells [49]. In addition, GPR109A is expressed in adipose tissues and activated adipose 
tissue macrophages where it regulates lipid homeostasis [47,50–52]. Olfactory receptor 78 (OLFR78) 
was identified as SCFAs in a ligand screen for orphan GPCRs [53]. OLFR78 is activated by acetate and 
propionate but not by butyrate; the EC50 value are 2.35mM and 920 μM, respectively. Olfr78 is 
expressed in blood vessels, especially localize in renal vessel where it is involved in renin secretion. The 
binding of gut microbiota-derived SCFAs to OLFR78 induces the release of renin, which is involved in 
the modulation of the blood pressure [53–55]. The metabolic effects of this SCFAs receptor are unclear 
to date. It is expected that further analysis will elucidate its function in energy metabolism. 
6. Epigenetic Regulation by SCFAs 
Gene expression is regulated by the modulation of histone acetylation by histone acetyltransferases 
and histone deacetylases (HDAC). SCFAs produced by gut microbes inhibit histone deacetylase activity 
and consequently modulate gene expression. Butyrate is the most potent inhibitor of HDAC, with a 
maximum efficiency of approximately 80% inhibition of HDAC1/2, and its in vitro Ki value is 
approximately 58 μM [56]. Propionate has a maximum inhibitory efficiently of approximately 60%. 
SCFAs function as non-competitive inhibitors of HDACs. It has been shown that butyrate and propionate 
selectively inhibit HDAC1 and HDAC3. With regard to the influence of the inhibition of HDAC by 
SCFAs on the host physiological functions, it has been reported that propionate and butyrate produced 
by gut microbes promote the generation of peripheral regulatory T-cells [57,58]. Gut microbe-derived 
butyrate induces the differentiation of colonic regulatory T cells by enhancing histone H3 acetylation in 
the promoter and conserved non-coding sequence regions of the Foxp3 locus, and reduces the 
development of colitis [58]. In addition, the putative link between the microbiota and epigenetic 
regulation has been examined in obese and type 2 diabetes patients as compared to lean control  
subjects [59]. The diversity of the gut microbiota and the degree of methylation of the FFAR3 promoter 
region were significantly lower in the obese and type 2 diabetic patients compared to lean individuals, 
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demonstrating a correlation between a higher body mass index and lower methylation of FFAR3 [59]. 
Therefore, epigenetic regulation may be also related to the beneficial effects by SCFAs on  
host metabolism. 
7. Conclusions 
In recent years, various host metabolic and immune response pathways have been reported to be 
related to diet and gut microbiota. Several studies have provided evidence that SCFAs, which are the 
end products of the fermentation of dietary fibers by the anaerobic intestinal microbiota, have beneficial 
effects on the host energy metabolism and inflammatory responses, because the host SCFA receptors 
and target molecules are expressed in both metabolic and immune tissues (Figure 1). As the 
inflammatory response is related to the development of obesity and type 2 diabetes, the SCFAs and their 
target molecules constitute potential therapeutic targets for the treatment of these diseases. Although the 
exact signaling mechanisms and physiological functions of SCFAs in the host peripheral tissues are 
unclear, a deeper understanding of the regulation of the energy metabolism and the inflammatory 
responses by the dietary SCFAs represents an important avenue for research in medicine and drug 
development for the prevention and treatment of obesity and type 2 diabetes. 
 
Figure 1. Effects of dietary gut microbial short-chain fatty acids (SCFAs) on the regulation 
of host metabolic functions. SCFAs affect host homeostasis through the stimulation of SCFA 
receptors, FFAR2, FFAR3, GPR109A and OLFR78. 
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